Drug recalls

Amlodipine and Olmesartan Medoxomil Tablets, 10mg/40mg, 30 Tablets, Rx only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed b…

Ascend Laboratories, LLC · Out of specification due to dissolution.

Class IIOngoingD-0045-2027
Status
Ongoing
City
Bedminster
State
NJ
Country
United States
Classification
Class II
Product type
Drugs
Event ID
100053
Recalling firm
Ascend Laboratories, LLC
Address 1
135 Us Highway 202 206 Ste 15
Postal code
07921-2608
Voluntary mandated
Voluntary: Firm initiated
Initial firm notification
Letter
Distribution pattern
Nationwide within the United States
Recall number
D-0045-2027
Product quantity
11,424 bottles.
Reason for recall
Out of specification due to dissolution.
Recall initiation date
20261006
Center classification date
20261016
Report date
20261028
Code info
Lot # 25120696, Exp Date: December 31, 2026.
Product description

Amlodipine and Olmesartan Medoxomil Tablets, 10mg/40mg, 30 Tablets, Rx only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-502-30.

Harmonized identifiers (openFDA)
Application number
ANDA209042
Brand name
AMLODIPINE AND OLMESARTAN MEDOXOMIL
Generic name
AMLODIPINE AND OLMESARTAN MEDOXOMIL
Manufacturer name
Ascend Laboratories, LLC
Product NDC
67877-499, 67877-500, 67877-501, 67877-502
Product type
HUMAN PRESCRIPTION DRUG
Route
ORAL
Substance name
AMLODIPINE BESYLATE, OLMESARTAN MEDOXOMIL
RxCUI
730861, 730866, 730869, 730872
SPL ID
32238052-6c4c-4b29-a59e-524c819c69f1
SPL set ID
c1204fbe-d086-43cf-bbaa-efec9cd0487c
Package NDC
67877-499-30, 67877-499-90, 67877-500-30, 67877-500-90, 67877-501-30, 67877-501-90, 67877-502-30, 67877-502-90
Is original packager
true
UNII
6M97XTV3HD, 864V2Q084H
Wholesale access for licensed clinicians.

Free to join: your NPI is checked against the federal registry at signup, then wholesale pricing and the professional shelves open.

Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.